Journal Information
Original
Full text access
Pre-proof, online 3 April 2025
Predictors of survival in metastatic malignant pleural effusions: the GASENT score
Visits
35
Juan Suárez-Antelo1, Lucía Ferreiro1,2,
Corresponding author
lferfer7@gmail.com

Corresponding Author: Servicio de Neumología, Hospital Clínico-Universitario de Santiago. Santiago de Compostela, Spain, Travesía da Choupana s/n, 15706 Santiago de Compostela, Spain
, José M. Porcel3, María Elena Toubes1, Óscar Lado-Baleato2,4, Nuria Rodríguez-Núñez1, Jorge Ricoy1, Adriana Lama1, Antonio Golpe1,2, José Manuel Álvarez-Dobaño1,2, Francisco Gude2,4,5,6, Luis Valdés1,2,6
1 Pulmonology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain
2 Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain
3 Pleural Medicine and Clinical Ultrasound Unit, Department of Internal Medicine, Arnau de Vilanova University Hospital, IRBLleida, Lleida, Spain
4 ISCIII Support Platforms for Clinical Research, Spain
5 Centro de Salud Concepción Arenal, Santiago de Compostela, Spain
6 Departamento de Medicina, Facultad de Medicina, Universidad de Santiago de Compostela, Spain
This item has received
Article information
Abstract

Objective: The therapeutic approach for metastatic malignant pleural effusion depends on the patient’s life expectancy. Can survival be accurately estimated in these patients using a risk-prediction model?

Methods: A prospective, single-center study was conducted to examine the prognostic value of pre-established variables (multivariate Cox model). Subsequently, a prognostic score was developed and validated. The inclusion period was 11 years long. Follow-up was conducted until death or for a minimum of 12 months.

Results: The derivation and validation cohorts included 475 and 205 patients, respectively. The prognostic score GASENT (Galicia, Age, Sex, ECOG-PS, Neutrophil/lymphocyte ratio, and Tumor type) was derived from the multivariate analysis of survival.

Categorization of patients in the derivation cohort into low-, moderate-, or high-risk yielded median survival times of 477 days (377–665; n=159), 108 days (83–156; n=158), and 35 days (27–47; n=158), respectively. Survival rates at 1, 3, and 6 months were 92%, 83%, and 72%, respectively, for the low-risk group; 80%, 55%, and 36%, respectively, for the moderate-risk group; and 55%, 23%, and 13%, respectively, for the high-risk group. The analysis of areas under the curve revealed that the GASENT model was superior to the LENT score as a survival predictive model at 1 (0.777 vs. 0.737; p=0.009), 3 (0.810 vs. 0.778; p=0.009), and 6 months (0.812 vs. 0.780; p=0.007).

Conclusions: The GASENT predictive model estimates survival in patients with metastatic malignant effusions with significantly greater accuracy than the scores categorizing patients by risk groups.

Key Words:
metastatic malignant pleural effusion
prediction model
survival analysis
Abbreviations:
AUC
ECOG-PS
GASENT
HR
LENT
MPE
MMPE
NLR
PF
VATS
95%CI
Full text is only available in PDF
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?